Clinical trials: Bladder Cancers
Bladder Cancer
Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer
This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline…
- Trial name
- ABATE (NCT04289779)
- Testing
- Cabozantinib, Atezolizumab, Cystectomy
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Deepak Kilari
Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
This phase II trial tests how well enfortumab vedotin (EV) and pembrolizumab works in treating patients with bladder cancer of variant histology (a group of less common types of bladder cancer) that have spread to nearby tissue…
- Conditions
- Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Neoplasm, Malignant Ureter Neoplasm
- Trial name
- NCT05756569
- Testing
- Biospecimen Collection, Computed Tomography, Enfortumab Vedotin
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Bladder Cancer
Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer
Open, multicentre, phase II trial of atezolizumab with concurrent normofractionated radiotherapy in patients with localized muscle-invasive bladder cancer treated with a selective multimodality bladder conservative approach.
- Trial name
- NCT04186013
- Testing
- Atezolizumab Injection [Tecentriq], External Beam Radiation Therapy (EBRT)
- Where
- 10 sites in Spain
- Volunteers
- 39 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Non-Small-Cell Lung Carcinoma, Prostate Cancer
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
Vorinostat (Suberoylanilide Hydroxamic Acid; NSC 701852) is a drug that inhibits an enzyme that plays a key role in the regulation of cell survival, growth, and eventual cell death, all of which play a role in cancer.
- Conditions
- Non-Small-Cell Lung Carcinoma, Prostate Cancer, Bladder Cancer, Urothelial Carcinoma
- Trial name
- NCT00565227
- Testing
- vorinostat (suberoylanilide hydroxamic acid), docetaxel
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Michigan Rogel Cancer Center
Bladder Cancer
Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Bladder Cancer
A Comprehensive Geriatric Assessment (CGA) is a set of tests used to evaluate a patient's medical, social, and functional status, and can identify impairments in these domains that may not be noticed otherwise.
- Trial name
- NCT04273724
- Testing
- Targeted Interventions for Impairments Identified During Geriatric Assessment
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-muscle Invasive Bladder Cancer (NMIBC)
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
This is an open-label, phase 2, randomized study of intravesical N-803 plus BCG (experimental arm A) and intravesical N-803 plus gemcitabine (experimental arm B) in participants who have intermediate-risk Ta/T1 papillary disease.
- Trial name
- NCT06829823
- Testing
- N-803 and BCG, N-803 and Gemcitabine
- Volunteers
- 20 people
- Sponsor
- ImmunityBio, Inc.
Prostate Cancer (Adenocarcinoma), Bladder Cancer
Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)
This trial tests if AI can help make medical info clear and readable. Many patients struggle to find medical informations that easy to read and understand from verified medical sources.
- Conditions
- Prostate Cancer (Adenocarcinoma), Bladder Cancer, Kidney Cancers, Testis Cancer
- Trial name
- NCT07568444
- Testing
- Pub2Post
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Prostate Cancer
Comparison of PET Imaging Patterns With PSMA and AR Expression in Prostate Cancer and Bladder Cancer
Patients suffering either from newly diagnosed very high risk locally advanced and/or oligometastatic prostate cancer (cohort A), metastatic castration-resistant prostate cancer (mCRPC, cohort B), newly diagnosed postate cancer…
- Trial name
- NCT05109884
- Testing
- PSMA PET Scan, FDHT PET Scan
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Medical University of Vienna
Bladder Neoplasm
Personalized Urine Biomarker for Patients With Bladder Cancer
Introduction Bladder cancer is the most common malignancy involving the urinary system and the ninth most common malignancy worldwide.
- Trial name
- NCT05467267
- Testing
- TURBT
- Volunteers
- 20 people
- Sponsor
- Ziv Hospital
Bladder Cancer
A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)
This is a Phase 1, multicenter, open-label study of intravesical Toca 511 followed by oral Toca FC in patients with high grade (HG) non-muscle invasive bladder cancer (NMIBC), with cohort expansion at the recommended Phase 2…
- Trial name
- NCT04089163
- Testing
- Toca 511, Toca FC (extended-release formulation of flucytosine)
- Sponsor
- Tocagen Inc.
Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma
Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer
This phase II trial studies the safety and feasibility of utilizing acupuncture in patients with high-risk bladder cancer that has not spread to the surrounding muscle (non-muscle invasive) undergoing treatment with Intravesical…
- Conditions
- Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
- Trial name
- NCT04496219
- Testing
- Acupuncture Therapy, BCG Solution, Best Practice
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Fred Hutchinson Cancer Center
Bladder Cancer, Colorectal Cancer
Mobile Ostomates Resources for Patients and Caregivers
The scope of this research is to examine the acceptability and feasibility of a refined web-based intervention ("STOMA Care" app) by conducting a randomized pilot consisting of bladder and colorectal cancer patients scheduled for…
- Trial name
- MORE (NCT06157814)
- Testing
- STOMA Care web-based application, Usual Care
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
HER2 Mutation-Related Tumors, HER2
A Phase 1/1b Study of IAM1363 in HER2 Cancers
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
- Conditions
- HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
- Trial name
- NCT06253871
- Testing
- IAM1363
- Where
- 53 sites in United States, France and 6 more
- Volunteers
- 383 people
- Sponsor
- Iambic Therapeutics, Inc
Lung Cancer, Head and Neck Cancer
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.
- Conditions
- Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer
- Trial name
- DELFI-L101 (NCT04825834)
- Testing
- Blood Sample Collection
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 2,992 people
- Sponsor
- Delfi Diagnostics Inc.
Bladder Cancer
Near Infrared Fluorescence Imaging for Bladder Cancer Detection
The primary outcome of this study is to determine the minimal dwell time needed for adequate detection of hexaminolevinulate HCL avid tumors using protoporphyrin IX (PpIX) near infrared fluorescence (NIRF).
- Trial name
- NCT03058705
- Testing
- Hexaminolevulinate HCL, Near Infrared Fluorescence (NIRF)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Edward Messing
Lung Neoplasm, Small Cell Carcinoma
Cone Beam CT Scanning in Lung and Bladder Cancer.
To study changes in tumor and normal organ size and/or position which occur during a course of radiation treatments.
- Conditions
- Lung Neoplasm, Small Cell Carcinoma, Bladder Carcinoma
- Trial name
- NCT00469066
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- AHS Cancer Control Alberta
Urinary Bladder Neoplasms
Antarctic Krill Oil Functional Food Mitigates Bladder Cancer Treatment Side Effects
This randomized, double-blind, placebo-controlled, multicenter trial evaluates the efficacy and safety of Antarctic krill oil in reducing side effects of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC).
- Trial name
- NCT06880939
- Testing
- Krill Oil Functional Food, Olive Oil
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Qilu Hospital of Shandong University
Urinary Tract Infection Bacterial, Benign Prostatic Hyperplasia
Closed-System Bladder Irrigation to Reduce Urinary Tract Infections After Endoscopic Urologic Surgery (IRIS Trial)
This randomized controlled trial evaluates whether a closed-system bladder irrigation device can reduce the incidence of urinary tract infections in patients undergoing endoscopic urologic surgery.
- Conditions
- Urinary Tract Infection Bacterial, Benign Prostatic Hyperplasia, Bladder Cancer
- Trial name
- IRIS (NCT07510685)
- Testing
- Closed-System Bladder Irrigation Flow Switch Device, Standard Bladder Irrigation
- Where
- Italy
- Volunteers
- 240 people
- Sponsor
- University of Pisa
Bladder Cancer
Quality of Life in Patients With Bladder Cancer
RATIONALE: Studying quality of life in patients with bladder cancer may help determine the long-term effects of bladder cancer and may help improve the quality of life for patients in the future.
- Trial name
- NCT00553215
- Testing
- quality-of-life assessment, questionnaire administration
- Where
- United Kingdom
- Volunteers
- 2,700 people
- Sponsor
- University of Birmingham
Bladder Cancer
PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
The primary objective of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of PF-07225570 alone or in combination with an anti-PD-1 antibody in participants with recurrent…
- Trial name
- NCT05259397
- Testing
- PF-07225570, sasanlimab
- Where
- 4 sites in United States, Poland
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.